Breast Cancer Therapeutics in Southeast Asia Markets to 2022 - Increasing Prevalence and Usage of Premium Targeted Therapies to Drive the Market

  • ID: 4229098
  • Report
  • Region: Asia, Asia Pacific
  • 176 Pages
  • GBI Research
1 of 5
In 2012 About 1.7 Million New Cases of Breast Cancer were Diagnosed Globally, Making it the Most Common Cancer in Women

FEATURED COMPANIES

  • AbbVie
  • BioMarin
  • Galena Biopharma
  • MacroGenics
  • Novartis
  • Pierre-Fabre
  • MORE

Breast cancer is a malignant neoplasm that begins in the breast tissue, which is made up of glands for milk production called lobules and the ducts that connect the lobules to the nipples. Most breast cancers are invasive cancers that have grown beyond the ducts or lobules and can metastasize to other parts of the body through the bloodstream and the lymphatic system (ACS, 2013a).

In 2012 about 1.7 Million new cases of breast cancer were diagnosed globally, making it the most common cancer in women. Previously the majority of these incident cases occurred in developed regions (such as the US, EU and Australia) while less developed countries (including several of the assessed Southeast Asian countries) had lower incidence.

The current market for breast cancer consists of chemotherapies, hormonal therapies and targeted therapies. Herceptin is the gold standard monoclonal antibody (mAb) for the treatment of HER2-positive disease, and is prescribed in nearly all settings. Although it is available in all of the assessed countries, its use is limited in the majority of Southeast Asian countries due to affordability issues, and limitations surrounding the diagnosis of HER2 status.

Furthermore, there is currently a very high unmet need in triple negative breast cancer (TNBC). Treatment has been largely dependent on traditional chemotherapies, which are clinically limited in terms of both efficacy and toxicity. There is therefore a need for more effective treatment options that provide substantial improvement in progression-free survival and overall survival.

In South Korea, Singapore and Taiwan the continued uptake of targeted therapies and other premium branded drugs will contribute to the ACoT. The premium therapies Kadcyla and Perjeta are due to be approved in Indonesia, Thailand, Vietnam and Malaysia during the forecast period. Despite a lower level of expected usage of these drugs in these countries, they will account for a significant share of the market in terms of value due to their superior efficacy and high price.

The report "Breast Cancer Therapeutics in Southeast Asia Markets to 2022 - Increasing Prevalence and Usage of Premium Targeted Therapies to Drive the Market" provides an introduction to breast cancer, detailing the etiology, tumor characteristics, epidemiology, diagnostic techniques, disease staging and typical prognoses for patients.

In depth, this report provides the following analysis:

  • Provides detailed analysis of the products currently marketed for breast cancer, detailing their key characteristics, including safety and efficacy, clinical trial outcomes, tolerability, dosing, administration, pricing, and overall competitive strength.
  • Provides detailed analysis of the pipeline for breast cancer by stage of development, molecule type, program type, mechanism of action and molecular target. It also analyzes recent clinical trials in this indication by enrollment, duration and failure rate, Analysis of contains market forecasts for the breast cancer market, covering epidemiology, treatment usage patterns, pricing and market size for the 2015-2022 forecast period.
  • Describes the major deals that have taken place in the SEA breast cancer market in recent years.

Scope

  • The current Southeast Asia breast cancer market contains well-established novel targeted products such as Perjeta and Kadcyla, tyrosine kinase inhibitors such as Tykerb, and CDK inhibitors such as Ibrance.
  • Which drugs are used as the standard treatment in each setting of the disease?
  • What are the competitive advantages of the existing novel drugs?
  • Do branded therapies show continued growth, and how does their expected uptake influence the market growth over the forecast period?
  • There are about 1,150 active pipeline molecules. The pipeline contains a range of molecule types and molecular targets, including those that are well established in breast cancer, and novel, first-in-class therapies.
  • Which molecular targets appear most frequently in the pipeline?
  • There is currently no approved therapy in the TNBC setting. Are there any drugs in the pipeline to improve treatment for TNBC?
  • Targets that are not currently represented by marketed products are virtually absent from the late-stage pipeline. Does the early stage pipeline have experimental molecules designed to target novel pathways?
  • Analysis of clinical trials since 2006 identified that the failure rates of breast cancer molecules were highest in Phase II, at 59%, with the overall attrition rate for breast cancer standing at 85%.
  • How do failure rates vary by stage of development, molecule type, and molecular target?
  • How do other factors, such as average trial duration and trial size, influence the costs and risks associated with product development?
  • The breast cancer Southeast Asian market will be valued at $2.7 billion in 2022, growing from $942.3m in 2015 at a CAGR of 16.2%.
  • Despite an array of treatments being available for breast cancer, there is still an unmet need in the Southeast Asian markets related to low uptake of targeted therapies. Will this scenario change during the forecast period?
  • Market forecasts indicate that South Korea will continue to be the largest market in Southeast Asia, due to the emergence of novel therapies and the continued uptake of branded therapies.
  • How will the annual cost of therapy and market size vary between the eight Southeast Asian markets?
  • What are the factors that contribute to the increase in ACoT and market size for each of the assessed countries?
  • How will branded therapies be affected by upcoming pipeline therapies in each of the assessed countries?
  • How will the potential launch of biosimilars influence each country?
  • Will the launch of biosimilars or emerging pipeline molecules threaten the commercial success of existing drugs?
  • Various drivers and barriers will influence the market over the forecast period.
  • What barriers limit the uptake of premium-priced therapeutics in the assessed countries?
  • What factors are most likely to drive the market in these countries?

Reasons to buy

This report will allow you to:

  • Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the treatment options available at each stage of diagnosis, including a clinical comparison of marketed therapies.
  • Visualize the composition of the breast cancer market in terms of dominant therapies, with their clinical and commercial standing. Unmet needs are also highlighted to allow a competitive understanding of gaps in the market.
  • Analyze the breast cancer pipeline and stratify pipeline therapies by stage of development, molecule type and molecular target.
  • Understand the potential of late-stage therapies, with extensive profiles of products that could enter the market over the forecast period, highlighting clinical performance, potential commercial positioning, and how they will compete with other therapies.
  • Predict breast cancer market growth in the eight Southeast Asian markets, with epidemiological and annual cost of therapy forecasts, as well as analysis of the contributions of promising late-stage molecules to market growth.
  • Identify commercial opportunities in the breast cancer deals landscape by analyzing trends in licensing and co-development deals.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AbbVie
  • BioMarin
  • Galena Biopharma
  • MacroGenics
  • Novartis
  • Pierre-Fabre
  • MORE

1 Introduction

2. Disease Introduction
2.1 Epidemiology
2.2 Symptoms
2.3 Etiology
2.4 Pathophysiology
2.5 Diagnosis
2.6 Prognosis and Disease Staging
2.7 Treatment Options
2.7.1 Surgery and Radiation Therapy
2.7.2 Chemotherapy
2.7.3 Hormonal Therapies
2.7.4 Targeted Therapies
2.8 Treatment Guidelines

3 Marketed Products
3.1 Overview
3.1.1 Herceptin (trastuzumab) - Genentech
3.1.2 Perjeta (pertuzumab) - Genentech
3.1.3 Afinitor (everolimus) - Novartis
3.1.4 Tykerb/Tyverb (lapatinib ditosylate monohydrate) - Novartis
3.1.5 Ibrance (palbociclib) - Pfizer
3.1.6 Ixempra (ixabepilone) - R-Pharm
3.1.7 Halaven (eribulin mesylate) - Eisai
3.1.8 Avastin (bevacizumab) - Genentech
3.1.9 Kadcyla (ado-trastuzumab emtansine) - Genentech
3.2 Comparative Efficacy and Safety of Marketed Products

4 Pipeline Analysis
4.1 Overview
4.2 Pipeline by Stage of Development, Molecule Type, Route of Administration and Program Type
4.2.1 Pipeline by Molecular Target
4.3 Promising Pipeline Molecules
4.3.1 Olaparib - AstraZeneca
4.3.2 Veliparib - AbbVie
4.3.3 Neratinib - Puma Biotechnology
4.3.4 Pembrolizumab - Merck & Co.
4.3.5 Ribociclib (Kisqali) - Novartis
4.3.6 Alpelisib - Novartis
4.3.7 Taselisib - Genentech
4.3.8 Vinflunine - Pierre-Fabre
4.3.9 Abemaciclib - Eli Lily
4.3.10 Niraparib - Tesaro
4.3.11 Buparlisib - Novartis
4.3.12 NeuVax (nelipepimut-S) - Galena Biopharma
4.3.13 Talazoparib - BioMarin
4.3.14 Atezolizumab - Roche
4.3.15 Entinostat - Syndax
4.3.16 Margetuximab - MacroGenics
4.3.17 OBI-822/821 - OBI Pharma
4.4 Comparative Efficacy and Safety of Pipeline Products
4.5 Product Competitiveness Framework

5 Clinical Trial Analysis
5.1 Failure Rate
5.1.1 Overall Failure Rate
5.1.2 Failure Rate by Phase and Molecule Type
5.1.3 Failure Rate by Phase and Molecule Target
5.2 Clinical Trial Duration
5.2.1 Clinical Trial Duration by Molecule Type
5.2.2 Clinical Trial Duration by Molecular Target
5.3 Clinical Trial Size
5.3.1 Patient Enrollment per Product by Molecule Type, Molecular Target and Stage of Development
5.3.2 Patient Enrollment per Trial by Molecule Type, Molecular Target and Stage of Development
5.4 Competitive Clinical Trials Metrics Analysis

6 Multi-scenario Forecast
6.1 Geographical Markets
6.2 Southeast Asian Markets
6.3 South Korea
6.3.1 Treatment Usage Patterns
6.3.2 Annual Cost of Therapy
6.3.3 Market Size
6.4 Singapore
6.4.1 Treatment Usage Patterns
6.4.2 Annual Cost of Therapy
6.4.3 Market Size
6.5 Taiwan
6.5.1 Treatment Usage Patterns
6.5.2 Annual Cost of Therapy
6.5.3 Market Size
6.6 Malaysia
6.6.1 Treatment Usage Patterns
6.6.2 Annual Cost of Therapy
6.6.3 Market Size
6.7 Philippines
6.7.1 Treatment Usage Patterns
6.7.2 Annual Cost of Therapy
6.7.3 Market Size
6.8 Thailand
6.8.1 Treatment Usage Patterns
6.8.2 Annual Cost of Therapy
6.8.3 Market Size
6.9 Vietnam
6.9.1 Treatment Usage Patterns
6.9.2 Annual Cost of Therapy
6.9.3 Market Size
6.10 Indonesia
6.10.1 Treatment Usage Patterns
6.10.2 Annual Cost of Therapy
6.10.3 Market Size

7 Drivers and Barriers
7.1 Drivers
7.1.1 Aging Population and Change in Lifestyle Habits
7.1.2 Increasing Awareness and Diagnosis
7.1.3 Potential Launch of Biosimilars to Increase Treatment Pool
7.1.4 Launch and Uptake of Pipeline Products and Continued Uptake of Existing Premium-Priced Therapies
7.2 Barriers
7.2.1 Inadequate Screening Programs and Social Factors
7.2.2 Lack of Proper Established Treatment Guidelines
7.2.3 Lack of Insurance and Adequate Publically Subsidized Services

8 Deals and Strategic Consolidations
8.1 Licensing Deals
8.1.1 Deals by Region and Value
8.1.2 Number of Disclosed and Undisclosed Deals by Year, Aggregate Deal Value
8.1.3 Deal Value by Stage of Development, Molecule Type, and Molecular Target
8.1.4 Key Licensing Deals
8.2 Co-development Deals
8.2.1 Deals by Region and Value
8.2.2 Number of Disclosed and Undisclosed Deals by Year, Aggregate Deal Value
8.2.3 Key Co-development Deals

9 Appendix
9.1 All Pipeline Drugs by Stage of Development
9.1.1 Discovery
9.1.2 IND/CTA- filed
9.1.3 Preclinical
9.1.4 Phase I
9.1.5 Phase II
9.1.6 Phase III
9.1.7 Pre-registration
9.2 Summary of Multi-Scenario Market Forecasts to 2022
9.2.1 Southeast Asia
9.2.2 South Korea
9.2.3 Singapore
9.2.4 Taiwan
9.2.5 Malaysia
9.2.6 Philippines
9.2.7 Thailand
9.2.8 Vietnam
9.2.9 Indonesia
9.3 Bibliography
9.4 Abbreviations
9.5 Research Methodology
9.5.1 Secondary Research
9.5.2 Marketed Product Profiles
9.5.3 Late-Stage Pipeline Candidates
9.5.4 Comparative Efficacy and Safety Heat Map for Marketed and Pipeline Products
9.5.5 Product Competitiveness Framework
9.5.6 Pipeline Analysis
9.5.7 Forecasting Model
9.5.8 Deals Data Analysis

List of Tables

Table 1: Breast Cancer Therapeutics, Global, Tumor, Nodes and Metastasis Staging, 2010-2013
Table 2: Breast Cancer Therapeutics, Southeast Asia, Five-year Survival Rate (%)
Table 3: Breast Cancer Therapeutics Market, Global, Licensing Deals in Southeast Asia and Deals with Disclosed Values, 2006-2016
Table 4: Breast Cancer Therapeutics Market, Global, Co-development Deals in Southeast Asia and Deals with Disclosed Values, 2006-2016
Table 5: Breast Cancer Therapeutics Market, Global, All Pipeline Products, Discovery, 2016
Table 6: Seasonal Influenza Therapeutics Market, Global, All Pipeline Products, IND/CTA- filed, 2016
Table 7: Breast Cancer Therapeutics Market, Global, All Pipeline Products, Preclinical, 2016
Table 8: Breast Cancer Therapeutics Market, Global, All Pipeline Products, Phase I, 2016
Table 9: Breast Cancer Therapeutics Market, Global, All Pipeline Products, Phase II, 2016
Table 10: Breast Cancer Therapeutics Market, Global, All Pipeline Products, Phase III, 2016
Table 11: Breast Cancer Therapeutics Market, Global, All Pipeline Products, Pre-registration Phase, 2016
Table 12: Breast Cancer Therapeutics Market, Southeast Asia, Market Forecast, 2015-2022
Table 13: Breast Cancer Therapeutics Market, South Korea, Market Forecast, 2015-2022
Table 14: Breast Cancer Therapeutics Market, Singapore, Market Forecast, 2015-2022
Table 15: Breast Cancer Therapeutics Market, Taiwan, Market Forecast, 2015-2022
Table 16: Breast Cancer Therapeutics Market, Malaysia, Market Forecast, 2015-2022
Table 17: Breast Cancer Therapeutics Market, Philippines, Market Forecast, 2015-2022
Table 18: Breast Cancer Therapeutics Market, Thailand, Market Forecast, 2015-2022
Table 19: Breast Cancer Therapeutics Market, Vietnam, Market Forecast, 2015-2022
Table 20: Breast Cancer Therapeutics Market, Indonesia, Market Forecast, 2015-2022

List of Figures

Figure 1: Breast Cancer Therapeutics, Southeast Asia, Age-Standardized Incidence (per 100,000 population), 2012
Figure 2: Breast Cancer Therapeutics, South Korea, Age-Specific Incidence (%), 2012
Figure 3: Breast Cancer Therapeutics, Southeast Asia, Age-Standardized Mortality (per 100,000 population), 2012
Figure 4: Breast Cancer Therapeutics, Global, Treatment Algorithm for Cancer Diagnosed at Stages I-III
Figure 5: Breast Cancer Therapeutics, Global, Treatment Algorithm for Cancer Diagnosed at Stage IV
Figure 6: Breast Cancer Therapeutics Market, Global, Heatmap, 2017
Figure 7: Breast Cancer Therapeutics Market, Global, Overview of Pipeline Products
Figure 8: Breast Cancer Therapeutics Market, Global, Molecular Target in the Pipeline
Figure 9: Breast Cancer Therapeutics Market, Southeast Asia, Lynparza, Market Forecast ($m), 2020-2022
Figure 10: Breast Cancer Therapeutics Market, Southeast Asia, Veliparib, Market Forecast ($m), 2020-2022
Figure 11: Breast Cancer Therapeutics Market, Southeast Asia, Neratinib, Market Forecast ($m), 2020-2022
Figure 12: Breast Cancer Therapeutics Market, Southeast Asia, Pembrolizumab, Market Forecast ($m), 2019-2022
Figure 13: Breast Cancer Therapeutics Market, Southeast Asia, Ribociclib, Market Forecast ($m), 2020-2022
Figure 14: Breast Cancer Therapeutics Market, Southeast Asia, Alpelisib, Market Forecast ($m), 2020-2022
Figure 15: Breast Cancer Therapeutics Market, Southeast Asia, Taselisib, Market Forecast ($m), 2020-2022
Figure 16: Breast Cancer Therapeutics Market, Southeast Asia, Vinflunine, Market Forecast ($m), 2018-2022
Figure 17: Breast Cancer Therapeutics Market, Global, Pipeline Heatmap, 2017
Figure 18: Breast Cancer Therapeutics Market, Competitor Matrix for Breast Cancer Marketed and Pipeline Products, 2017
Figure 19: Breast Cancer Therapeutics Market, Global, Average Clinical Trial Failure Rate (%), 2006-2016
Figure 20: Breast Cancer Therapeutics Market, Global, Clinical Trial Failure Rates by Molecule Type (%), 2006-2016
Figure 21: Breast Cancer Therapeutics Market, Global, Clinical Trial Failure Rates by Molecular Target (%), 2006-2016
Figure 22: Breast Cancer Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Molecule Type (months), 2006-2016
Figure 23: Breast Cancer Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Molecular Target (months), 2006-2016
Figure 24: Breast Cancer Therapeutics Market, Global, Clinical Trial Size per Product by Molecule Type (participants), 2006-2016
Figure 25: Breast Cancer Therapeutics Market, Global, Clinical Trial Size per Product by Molecular target (participants), 2006-2016
Figure 26: Breast Cancer Therapeutics Market, Global, Clinical Trial Size per Individual Trial by Molecule Type (participants), 2006-2016
Figure 27: Breast Cancer Therapeutics Market, Global, Clinical Trial Size per Individual Trial by Molecular Target (participants), 2006-2016
Figure 28: Breast Cancer Therapeutics Market, Global, Comparison of Average Trial Metrics by Phase and Molecule Type
Figure 29: Breast Cancer Therapeutics Market, Global, Comparison of Average Trial Metrics by Phase and Molecular Target
Figure 30: Breast Cancer Therapeutics Market, Southeast Asia, Treatment Usage Pattern (‘000), 2015-2022
Figure 31: Breast Cancer Therapeutics Market, Southeast Asia, Market Size ($bn), 2015-2022
Figure 32: Breast Cancer Therapeutics Market, South Korea, Treatment Usage Patterns (‘000), 2015-2022
Figure 33: Breast Cancer Therapeutics Market, South Korea, Annual Cost of Therapy ($), 2015-2022
Figure 34: Breast Cancer Therapeutics Market, South Korea, Market Size ($m), 2015-2022
Figure 35: Breast Cancer Therapeutics Market, Singapore, Treatment Usage Patterns (‘000), 2015-2022
Figure 36: Breast Cancer Therapeutics Market, Singapore, Annual Cost of Therapy ($), 2015-2022
Figure 37: Breast Cancer Therapeutics Market, Singapore, Market Size ($m), 2015-2022
Figure 38: Breast Cancer Therapeutics Market, Taiwan, Treatment Usage Patterns (‘000), 2015-2022
Figure 39: Breast Cancer Therapeutics Market, Taiwan, Annual Cost of Therapy ($), 2015-2022
Figure 40: Breast Cancer Therapeutics Market, Taiwan, Market Size ($m), 2015-2022
Figure 41: Breast Cancer Therapeutics Market, Malaysia, Treatment Usage Patterns (‘000), 2015-2022
Figure 42: Breast Cancer Therapeutics Market, Malaysia, Annual Cost of Therapy ($), 2015-2022
Figure 43: Breast Cancer Therapeutics Market, Malaysia, Market Size ($m), 2015-2022
Figure 44: Breast Cancer Therapeutics Market, Philippines, Treatment Usage Patterns (‘000), 2015-2022
Figure 45: Breast Cancer Therapeutics Market, Philippines, Annual Cost of Therapy ($), 2015-2022
Figure 46: Breast Cancer Therapeutics Market, Philippines, Market Size ($m), 2015-2022
Figure 47: Breast Cancer Therapeutics Market, Thailand, Treatment Usage Patterns (‘000), 2015-2022
Figure 48: Breast Cancer Therapeutics Market, Thailand, Annual Cost of Therapy ($), 2015-2022
Figure 49: Breast Cancer Therapeutics Market, Thailand, Market Size ($m), 2015-2022
Figure 50: Breast Cancer Therapeutics Market, Vietnam, Treatment Usage Patterns (‘000), 2015-2022
Figure 51: Breast Cancer Therapeutics Market, Vietnam, Annual Cost of Therapy ($), 2015-2022
Figure 52: Breast Cancer Therapeutics Market, Vietnam, Market Size ($m), 2015-2022
Figure 53: Breast Cancer Therapeutics Market, Indonesia, Treatment Usage Patterns (‘000), 2015-2022
Figure 54: Breast Cancer Therapeutics Market, Indonesia, Annual Cost of Therapy ($), 2015-2022
Figure 55: Breast Cancer Therapeutics Market, Indonesia, Market Size ($m), 2015-2022
Figure 56: Breast Cancer Therapeutics Market, Global, Licensing Deals by Region and Value, 2006-2016
Figure 57: Breast Cancer Therapeutics Market, Global, Number of Disclosed and Undisclosed Licensing Deals by Year, Aggregate Deal Value and Aggregate Upfront Payment Value, 2006-2016
Figure 58: Breast Cancer Therapeutics Market, Global, Licensing Deals by Stage of Development, Deal Value and Upfront Payment Value, 2006-2016
Figure 59: Breast Cancer Therapeutics Market, Global, Licensing Deals by Molecule Type and Stage of Development, 2006-2016
Figure 60: Breast Cancer Therapeutics, Global, Licensing Deals by Molecular Targets and Aggregate Deal Value ($), 2006-2016
Figure 61: Breast Cancer Therapeutics Market, Global, Co-development Deals by Region, 2006-2016
Figure 62: Breast Cancer Therapeutics Market, Global, Number of Disclosed and Undisclosed Co-development Deals by Year, Aggregate Deal Value and Aggregate Upfront Payment Value, 2006-2016
Figure 63: Breast Cancer Therapeutics Market, Global, Co-development Deals by Stage of Development, 2006-2016
Figure 64: Breast Cancer Therapeutics Market, Global, Co-development Deals by Molecule type and Stage of Development, 2006-2016
Figure 65: Breast Cancer Therapeutics Market, Global, Co-development Deals by Molecular Target, 2006-2016

Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • AbbVie
  • AstraZeneca
  • BioMarin
  • Eli Lily
  • Galena Biopharma
  • Genentech
  • MacroGenics
  • Merck & Co.
  • Novartis
  • OBI Pharma
  • Pierre-Fabre
  • Puma Biotechnology
  • Roche
  • Syndax
  • Tesaro
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll